OMNISCAN

This brand name is authorized in United States. It is also authorized in Brazil, Canada, Croatia, Cyprus, Estonia, Hong Kong SAR China, Japan, Lithuania, New Zealand, Poland, Singapore, South Africa.

Active ingredients

The drug OMNISCAN contains one active pharmaceutical ingredient (API):

1	Gadodiamide UNII 84F6U3J2R6 - GADODIAMIDE
	Gadodiamide is a paramagnetic contrast agent (GBCA), with imaging activity upon magnetic resonance imaging (MRI). Gadodiamide activity enhances the visualization of the tissues.
	Read more about Gadodiamide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V08CA03	Gadodiamide	V Various → V08 Contrast media → V08C Magnetic resonance imaging contrast media → V08CA Paramagnetic contrast media
Discover more medicines within V08CA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	541613060001904, 541613060002004, 541613060002104
CA	Health Products and Food Branch	02172771
EE	Ravimiamet	1005871, 1079513, 1079524, 1079535, 1151569, 1151570, 1626342
HK	Department of Health Drug Office	43493
HR	Agencija za lijekove i medicinske proizvode	HR-H-717692685, HR-H-725785510
JP	医薬品医療機器総合機構	7290408A1036, 7290408G1039, 7290408G2035, 7290408G3031, 7290408G4038
LT	Valstybinė vaistų kontrolės tarnyba	1008753, 1008754, 1008755, 1008756, 1071660
NZ	Medicines and Medical Devices Safety Authority	6848
PL	Rejestru Produktów Leczniczych	100049523
SG	Health Sciences Authority	08521P
US	FDA, National Drug Code	0407-0690, 0407-0691
ZA	Health Products Regulatory Authority	29/28/0563, 29/28/0564, 29/28/0565, 30/28/0159